Onishi T, Ohishi Y, Iizuka N, Suzuki Y, Shirakawa H, Hatano T, Tomita M
Department of Urology, Jikei University School of Medicine.
Nihon Hinyokika Gakkai Zasshi. 1995 Oct;86(10):1538-42. doi: 10.5980/jpnjurol1989.86.1538.
A solitary metastasis from renal cell carcinoma is rarely occurred evidence. Therefore, we intended to study on the clinical characteristics of those patients who developed a solitary pancreatic metastasis after nephrectomy.
Of seven hundred and fifty-two patients with renal cell carcinoma (RCC) who had been treated during the past 38 years, 7 patients developed a solitary pancreatic metastasis after nephrectomy. We studied on the clinical characteristics, treatment modalities and prognosis of these 7 patients.
Regarding the age distribution at the time of nephrectomy, the median age was 48 years old. Therefore, the median age of patients developing a pancreatic metastasis was 10 years younger than that of the whole group of RCC. Regarding the sex ratio of these 7 patients, there was no difference between the male and female group (male in 4, female in 3). Therefore, relatively higher rate of pancreatic metastasis in female patients was observed compared with the male counterpart. Furthermore, no difference in the affected side of the primary tumour was observed in these 7 patients (left in 4, right in 3). Regarding the stages at the time of nephrectomy, a majority of patients (85.7%) showed low stages (stages 1 and 2). As to the grade of primary lesion, a majority of these tumours (85.7%) showed low grades (grades I and II). In an analysis of the interval from the time of nephrectomy to the pancreatic metastasis, the median interval was 140 months. Therefore, the percentage of the late recurrent patients was 71.4%. As to the site of metastasis in the pancreas, various sites in the pancreas was affected, with dominant site being its body. The median size of metastatic lesion was 4.25 cm. Regarding the treatment of pancreatic metastasis, resection of the metastasis was performed in 5 patients, and the remaining 2 patients received chemotherapy in combination with administration of interferon. As to the clinical courses of these 7 patients, other organs became involved with metastases in 6 patients, and 5 of them died with the median survival of 18 months. Furthermore, of the remaining 2 patients, one survived for 73 months with persistent cancer, and the other survived for 4 months without cancer.
In conclusion, renal cell carcinoma accompanied by later development of pancreatic metastasis tend to occur in younger patients and have higher incidence in females than in males when compared with otherwise similar renal cell carcinomas. Furthermore, they tend to be of low stage and grade, have longer intervals to the occurrence of metastasis and carry a poor prognosis.
肾细胞癌发生孤立性转移的证据很少见。因此,我们旨在研究肾切除术后发生孤立性胰腺转移患者的临床特征。
在过去38年中接受治疗的752例肾细胞癌(RCC)患者中,7例在肾切除术后发生了孤立性胰腺转移。我们研究了这7例患者的临床特征、治疗方式和预后。
关于肾切除时的年龄分布,中位年龄为48岁。因此,发生胰腺转移患者的中位年龄比整个RCC组年轻10岁。关于这7例患者的性别比例,男性组和女性组之间没有差异(男性4例,女性3例)。因此,与男性相比,女性患者胰腺转移的发生率相对较高。此外,这7例患者的原发肿瘤患侧没有差异(左侧4例,右侧3例)。关于肾切除时的分期,大多数患者(85.7%)为低分期(1期和2期)。至于原发病变的分级,这些肿瘤中的大多数(85.7%)为低分级(I级和II级)。在分析从肾切除到胰腺转移的间隔时间时,中位间隔为140个月。因此,晚期复发患者的比例为71.4%。至于胰腺转移的部位,胰腺的各个部位均受影响,主要部位是胰体。转移灶的中位大小为4.25 cm。关于胰腺转移的治疗,5例患者进行了转移灶切除,其余2例患者接受了化疗联合干扰素治疗。至于这7例患者的临床病程,6例患者的其他器官出现转移灶,其中5例患者死亡,中位生存期为18个月。此外,在其余2例患者中,1例患者带瘤存活73个月,另1例患者无瘤存活4个月。
总之,与其他情况相似的肾细胞癌相比,伴有胰腺转移的肾细胞癌往往发生在较年轻的患者中,女性的发病率高于男性。此外,它们往往分期和分级较低,转移发生的间隔时间较长,预后较差。